Furthermore, 61 percent of females undergoing chemotherapy were hospitalized for a few medical reason – – whether it was chemotherapy related – – compared with 42 percent of females with breast malignancy who were not going through chemotherapy treatment . The experts also reported that ladies undergoing chemotherapy who experienced side effects spent $16,000 more for outpatient treatment, $13,000 even more for hospital treatment and $1,900 even more for prescription drugs than ladies undergoing chemotherapy who did not experience such problems .Licensing partner ‘This is actually the second such licensing contract with Athena Diagnostics that CAMH has signed within a few weeks. It is an exciting time for CAMH to partner with Athena Diagnostics in bringing new tools to the clinicians who are assisting clients and their families learn even more about the chance factors associated with inherited conditions,’ says Dr. Bruce G. Pollock, VP of Study at CAMH. ‘Dr. Vincent includes a remarkable research and publications record in this certain area. We are proud of his work and of the support that the CAMH Analysis Program is bringing to the individuals who have, or are at risk of having, inherited conditions,’ Dr. Pollock adds. The cost of the test – which is available only through scientific services – has however to be determined.